A recent clinical report on FT596, an iPSC-derived CD19 CAR NK cell therapy, demonstrated good tolerance and encouraging outcomes in patients with relapsed or refractory B cell lymphoma, achieving an complete response rate of 85% in follicular lymphoma, 64% in aggressive large-cell lymphomas excluding de novo diffuse large B cell lymphoma, and 30% among 20 patients who had previously failed CD19 CAR T cell therapy (5). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.